Company intelligence / Profile preview
NeuroEnergy Ventures
New York, New York, United Statesneuro-energy.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuroEnergy Ventures is launching its first commercial medical food, Neuridan, in late 2024 for the dietary management of impaired brain glucose metabolism in Alzheimer's Disease and mild cognitive impairment. The company has extensive clinical research supporting safety and additional preclinical/early clinical programs for other indications in neurology.
- Therapeutic areas
- Neurology
- Modalities
- Medical foodSmall moleculeKetone body ester
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NeuroEnergy Ventures.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroEnergy Ventures.